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Abstract
Background: Probiotics may prevent antibiotic-associated and Clostridium difficile-associated diarrhoea (AAD/
CDAD). Many spinal cord injury centre (SCIC) practitioners consider probiotics generically and may not realise that
efficacy can be strain-, dose- and disease-specific. In order to confirm these effects and fully evaluate the extent of
probiotic effectiveness in these patients, a systematic review and meta-analysis is indicated.
Methods: The following databases will be searched for relevant studies: Cochrane Library; Centre for Reviews and
Dissemination (CRD) Database; CINAHL; PsycINFO; Embase; Medline; AMED; International Clinical Trials Registry
Platform Search Portal and ISRCTN Registry and will hand search a list of conference proceedings. Any randomised
controlled trials without restriction of publication status will be included with treatment of AAD/CDAD. Outcomes
will include the effect of probiotic on the occurrence of AAD/CDAD and duration of diarrhoea, intensive care unit
admission, hospital mortality and length of hospital stay. Two reviewers will independently screen the titles,
abstracts or even full texts and extract data. Two other reviewers will assess study quality. Revman 5.1 software will
be used to conduct meta-analysis and calculate the risk ratio for dichotomous data. Weighted mean difference or
standard mean difference will be calculated for continuous data. The Cochrane Collaboration’s tool will be used to
assess the risk of bias.
Discussion: This systematic review protocol will provide information on probiotic therapy for AAD and CDAD in
spinal cord injury (SCI) population. The results will be disseminated through peer-reviewed publication or
conference presentation.
Systematic review registration: PROSPERO CRD42015016976
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Background
Introduction
Data on the prevalence of diarrhoea associated with anti-
biotic used (AAD) and Clostridium difficile (CDAD) in
spinal cord injury (SCI) patients is limited. Recent meta-
analysis examining randomised, double-blinded, con-
trolled trials of probiotics in the prevention of AAD [1–4]
and CDAD [4] suggest the use of probiotic is associated
with a reduction in diarrhoea compared to placebo. How-
ever, the heterogeneity of the studies (varies in study
population, sample size, probiotic strains, dose and dur-
ation of probiotic and definition of diarrhoea) makes it
very difficult to draw definite conclusions. Many physi-
cians and consumers view all probiotics as being the same
and therefore could apply to all populations. SCI are life-
changing events that have significant medical, physical,
socio-psychological effects. After SCI, patients are re-
quired to stay in SCI centres for an extended period of
time before they can re-integrate back into community.
Indeed, SCI patients are more vulnerable in developing
AAD/CDAD as they tend to stay in hospitals for an ex-
tended period of time after an SCI and the use of antibi-
otics are common. We are not aware of any published
systematic review reporting the effectiveness of probiotics
in preventing or treating diarrhoea in SCI patients. It ap-
peared logical to assess probiotics in SCI patients because
these patients are particularly vulnerable to diarrhoea and
its consequences for many reasons, such as the increased
use of antibiotics for treating urinary tract infection due to
increased catheter use [5]. Diarrhoea can delay rehabilita-
tion, increase the risk of developing pressure ulcers/delay
wound healing and reduce quality of life [5].
Description of the intervention
Probiotics are live organisms that, when administered in
optimum amounts, confer a health benefit on the host
[6]. They are increasingly available as capsules and
dairy-based food products sold in supermarkets and
health food shops. Although there are numerous com-
mercially available probiotics, there is much debate as to
what beneficial effects these provide and which specific
organisms may be most effective in any specific patient
group [3, 7, 8]. Microorganisms commonly used in pro-
biotic preparations include bacteria of the genera Lacto-
bacillus, Bifidobacterium, Escherichia, Enterococcus or
Bacillus and the fungal genus Saccharomyces [8].
How the intervention might work
Probiotics that colonise the gastrointestinal tract (GI) ef-
fectively help resist gut colonisation by potentially harm-
ful bacteria. Such probiotics often have additional
properties that benefit the host [8, 9]. Certain Lactoba-
cillus strains can produce antimicrobial compounds,
known as bacteriocins, which may inhibit pathogens
such as Bacillus, Staphylococcus and Enterococcus spe-
cies. A specific strain of Lactobacillus acidophilus pro-
duces a bacteriocin that has shown to inhibit strains of
Listeria innocua and Listeria monocytogenes [7].
Why it is important to perform this review
Different probiotic species and strains can have substan-
tially different effects on the host [9, 10]. Several species-
and strain-specific factors play a role in determining
what benefits, if any, a probiotic may confer. To exert a
beneficial effect, a probiotic must first be able to colon-
ise the GI tract. The initial step required for GI colonisa-
tion by probiotics is adhesion to the GI mucosa [11].
Although not fully understood, current evidence sug-
gests that the adhesive characteristics of probiotics may
be due to differences in the expression of large surface
proteins and their interaction with mucus-binding pro-
teins [11]. Probiotics have been suggested as a means of
preventing adverse GI conditions such as antibiotic-
associated diarrhoea (AAD) and Clostridium difficile-as-
sociated diarrhoea (CDAD) [3, 7, 10, 12]. However, this
is not a characteristic that is shared amongst all pro-
biotic strains [8–11], and effects may differ with different
patient groups [9, 12]. One example where the use of
probiotics is particularly likely to be beneficial is in pa-
tients with SCI who not only require an extended period
of stay in hospital but also have increased risk of infec-
tion due to the use of urinary catheters for long-term
bladder management. If diarrhoea develops, rehabilita-
tion will be delayed, impacting not just on the patient
but also causing significant extra healthcare costs. Given
the severe loss of quality of life for SCI patients, if any
probiotic is effective, their low cost as well as the low in-
cidence of adverse events [6] render probiotics an at-
tractive intervention to prevent AAD/CDAD.
Anecdotally, it has been noted that many practitioners
consider probiotics in generic terms, not recognising
that there may be differences between different products.
Similarly, some of the healthcare facilities stock a pro-
biotic but will not substitute one commercial probiotic
for another based on cost or availability, and without re-
gard for any scientific evidence to support the probiotic
in question.
With this in mind, it is important to recognise that
there is no ‘generic equivalency’ between probiotic spe-
cies and strains. In clinical practice, it is important for
clinicians to use or recommend specific commercially
available probiotics that have specifically been shown to
have beneficial effects in clinical trials.
To address this issue, we plan to conduct a systematic
review and meta-analysis to determine: (1) if probiotic is
effective in preventing or treating diarrhoea associated
with antibiotic use and Clostridium difficile infection; (2)
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what is the optimal dose, duration and frequency of pro-
biotics in SCI patients.
Methods and analysis
Eligibility criteria for included studies
Type of studies
Randomised Controlled Trials (RCTs) in English will be
included without restriction of publication type.
Participants
Participants aged 18 years and over, any race or gender
with a diagnosis of spinal cord injury (according to the
definition of the International Standards for neurological
classification of spinal cord injury and American Spinal
Injury Association (ASIA) Impairment Scale (AIS) A-D
[13]) will be eligible for the systematic review and meta-
analysis.
Type of intervention
Probiotic administration (all strains and dose informa-
tion will be recorded) in the intervention group must be
given within 5 days of antibiotic commencement. The
control group should receive either placebo or routine
clinical care. The reason we would like to ensure the
study administered probiotics within 5 days of antibiotic
commencement is due to minimising the risk of dysbio-
sis [14].
Study end points/main outcomes
The primary study end points include the incidence of
diarrhoea associated with antibiotic use and Clostridium
difficile infection. The definition of diarrhoea and occur-
rence of AAD/CDAD and its follow-up period will be
recorded as per identified paper.
The secondary end points include duration of diar-
rhoea, Intensive Care Unit (ICU) admission, hospital
mortality, length of hospital stay and occurrence of ad-
verse events.
Search methods for identifying studies
Electronic searches
We will systematically search Cochrane Library, Centre
for Reviews and Dissemination (CRD), CINAHL, Psy-
cINFO, Embase, Medline and AMED from inception to
27th February 2015. We will also screen the reference
lists of relevant studies and reviews for additional arti-
cles. In addition, we will search the following websites
for unpublished or ongoing studies: International Clin-
ical Trial Registry Platform Search Portal (http://
www.who.int/ictrp/search/en/) and ISTCTN registry
(http://www.controlled-trials.com) and review abstracts
from selected scientific proceedings (Proceeding of the
Nutrition Society of the Nutrition Society of the UK and
Clinical Nutrition Supplement or e-ESPEN of the
European Society of Parenteral and Enteral Nutrition).
We will apply a language filter in this study. Studies re-
ported in non-English language will be excluded.
Search terms/search strategy
The keywords and Medical Subject Headings related to
probiotic (lactobacillus, bifidobacter*, bifidobacillus,
streptococc*, lactococc*, leuconostoc, pediococc*, sac-
charomyce, probiotic and synbiotic), diarrhoea (anti-
biotic associated, Clostridium difficile associated) and
SCI patients (spine injury, cervical injury, spine fracture,
vertebra compression, vertebra dislocation, quadriplegia,
paralysis, paraplegia, tetraplegia, paraplegia, thoracic in-
jury, lumbar injury, sacral injury) will be used alone or
in combination (and with synonyms and closely related
words) to retrieve relevant articles. The search strategies
have been developed (see Additional file 1 for Medline/
Embase/CINAHL/AMED/PsycINFO/Cochrane/Centre
for Reviews and Dissemination/International Clinical
Trials Registry), and a similar search strategy will be
adapted for the other databases.
Data collection and analysis
Three reviewers (SW, SH and EM) will independently
examine the titles and/or abstracts and eliminate irrele-
vant studies. The full text of all potential eligible studies
will be read and their suitability for inclusion determined
according to the PICO (participant, intervention, com-
parison and outcomes) model. Discrepancy will be re-
solved by consensus or discussion with other reviewers
(AJ, JO’D). Inter-rater agreement will be assessed using
the kappa statistics (Κ < 0.01: no agreement; Κ: poor
agreement; Κ = 0.21–0.4: fair agreement; Κ = 0.41–0.6:
moderate agreement; Κ = 0.61–0.8: good agreement; Κ =
0.81–1: very good agreement) [15]. Details of the study
selection procedure are shown in Fig. 1. Excluded stud-
ies will be listed in a table with the reasons for exclusion
outlined.
Data extraction
All abstract data extracted from the retrieved trials will
be reviewed independently using a predefined data ex-
traction sheet. Any discrepancy will be managed by con-
sensus. The following variables will be recorded for each
study: the name of the first author, publication year,
country of origin, type of setting (SCI centres, general
hospital, community), patients’ characteristics (gender,
age, number, inclusion and exclusion criteria), character-
istics of interventions (type of probiotics, concentration,
route, dose and duration of intervention), characteristics
of control methods, and outcomes (occurrence of diar-
rhoea, mortality, ICU admission, the length of hospital
stay and adverse event data, in two groups). If necessary
(unclear data, missing data and extractable data), we will
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attempt to contact the corresponding authors of the in-
cluded studies for missing data and for clarification.
Risk of bias assessment
The reviewers will independently assess the risk of bias
using the assessment tool from the Cochrane Collabor-
ation [16]. The following sources of bias will be detected:
selection bias (random sequence generation and alloca-
tion concealment), detection bias (blinding of outcome
assessment), blinding of participants and personnel (per-
formance bias), attrition bias (incomplete outcome data),
reporting bias (selective outcome reporting) and industry
bias. The studies will then be classified into three levels
of bias: low, unclear and high risk bias. Differences in
opinion will be resolved by discussion or consultation
with third reviewer (EM).
Assessment of the quality of included studies
The quality of the evidence will be rated according to
the GRADE guidelines [17, 18].
Dealing with missing data
If there is any missing or insufficient data in included
studies, we will contact the corresponding authors of the
study by email or telephone to obtain more information.
If we are unable to obtain the missing data, the method
reported by the Cochrane Handbook for Systematic Re-
views of Intervention [16] will be used to perform
complete case analysis, and a sensitivity analysis will also
be conducted to assess the impact of including studies
with 20 % or more of missing data. For all outcomes, we
will conduct intention-to-treat analysis wherever
possible.
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Fig. 1 Process of the systematic review
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Statistical analysis
Revman (version 5.1) software will be used to conduct a
meta-analysis and calculate the OR and 95 % confidence
interval (CI) for dichotomous data. Weighted mean differ-
ence (WMD) or standard mean difference (SMD) and
95 % CI will be calculated for continuous data. If the same
outcome measurement tool and unit was used, the WMD
and 95 % CI will be calculated, or otherwise the SMD and
95 % CI. To account for differences between probiotic in-
terventions (different strains and dose), sub-group ana-
lyses by intervention will be conducted (if we identified
more than three studies using similar probiotic strains). If
the intervention are too varied, data will not be pooled.
Given the heterogeneity of study designs, probiotic
strains and dosing regimens, a conservative approach will
be employed for all analyses based on a random effect
model. The RR, WMD or SMD will be calculated by the
random-effect model. Forest plot will be generated to illus-
trate the study-specific effect sizes along with a 95 % CI.
Assessment of heterogeneity
Heterogeneity will be assessed using Cochran’s Q statis-
tic and Higgins I2 statistic, where I2 > 50 % indicates the
presence of significant heterogeneity. I2 will be calcu-
lated according to the equation I2 = 100 % × (Q-df )/Q,
where Q is the Cochran heterogeneity statistic [19].
Sensitivity analysis
The sensitivity analysis will be used to assess whether
the sample size and missing data impact on the results
of the review. If there are adequate studies (not less than
three studies), we will conduct a sensitivity analysis to
check the robustness of conclusions and assess the im-
pact of methodological quality.
For sensitivity analyses, we will perform meta-analyses
using fixed effects models and assess the consistency of
our results across random-effect models and fixed effects
models.
Assessment of publication bias
A funnel plot will be used to evaluate publication bias if
more than ten studies are included. A symmetrical fun-
nel plot usually suggests an absence of publication bias.
However, asymmetry in a funnel plot can be explained
by other factors including publication bias and differing
study quality [20]. We will also use Egger’s test [21] to
qualitatively detect publication bias.
Ethics and dissemination
Ethics approval is not required as this is a protocol for a
systematic review. The findings will be disseminated in a
peer-reviewed journal and presented at a relevant con-
ference. The study is registered at PROSPERO, the
International Prospective Register of Systematic Reviews,
at the University of York (CRD 42015016976).
Discussion
This systematic review and meta-analysis will use the
most definitive method to assess the effectiveness of pro-
biotic in preventing and treating diarrhoea associated
with antibiotics and Clostridium difficile infection in SCI
population.
The current use of probiotic to prevent and treat AAD/
CDAD remains inconclusive, where it could be limited by
variation in strain, dose, duration and disease-type studied.
This systematic review and meta-analysis will examine the
potential impact of probiotic intervention in preventing or
treating AAD/CDAD in SCI patients. Other specific aims
that will be addressed by this study include determining
the strains, optimal dose and duration of probiotic and the
safety profile of probiotics. If probiotics are found to be ef-
fective, this may support the need for routine prescrip-
tions to SCI patients as prophylactic or to treat AAD/
CDAD. The collaboration formed through this study will
be the platform to conduct further a systematic review
and meta-analysis for the probiotic management and pre-
vention of diarrhoea in SCI patients.
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